use of pegylated variants of igf-i for the treatment of neuromuscular disorders

摘要

use of pegylated variants of igf-i for the treatment of neuromuscular disorders. the present invention relates to the pharmaceutical use of igf-i polyethylene glycol (peg) variants for the treatment, prevention and / or delaying the progression of neuromuscular disorders, in particular amyotrophic lateral sclerosis (als). more specifically, the present invention relates to the use of a pegylated variant of igf-i for the production of a pharmaceutical composition for the treatment, prevention and / or delay of neuromuscular disorders, in particular where the pegylated variant of igf- i is characterized by the fact that it is derived from the amino acid sequence of wild-type human igf-i (seq id no: 1) and carries one or two amino acid changes at amino acid positions 27, 65 and 68 so that one or two amino acids at positions 27, 65 and 68 is / are a poiar amino acid but not lysine and peg is attached to at least one lysine residue.